Introduction

When joint cartilage is worn or damaged, the first question most patients ask is whether anything can be done without an operation. Several injectable products have been developed with that goal in mind. They are not equivalent: they differ in what they are made of, how they are applied, what regulatory approval they carry, and what the clinical evidence shows. Understanding those differences helps you weigh the options with your clinician before committing to anything.

How These Injectable Products Work

Although all three options discussed here are delivered into or around a joint, their mechanisms are quite different.

ChondroFiller is a Class III CE-marked, acellular (cell-free) Type I collagen hydrogel scaffold. It is manufactured by Meidrix Biomedicals in Germany and imported into the UK under prescription. When injected under ultrasound guidance into the joint as an outpatient procedure, it fills the cartilage defect and self-gels within approximately three to five minutes at body temperature. The scaffold then acts as a chemotactic matrix, recruiting the patient's own progenitor cells from the surrounding synovium and subchondral bone to migrate in, proliferate, and differentiate toward cartilage tissue. It does not contain cells itself; instead it provides the structural environment for the body's own repair response. It is best understood as a biologically active support scaffold rather than a pain-relief injection or a cure for arthritis.

Spherox is a cell-based product that uses the patient's own chondrocytes. These cells are harvested in a first procedure, cultured and expanded in a laboratory over several weeks, and then implanted in a second procedure. Spherox has regulatory approval for selected knee cartilage defects in parts of Europe. Because it requires two separate interventions and a laboratory stage, the overall process is considerably more involved than a single-stage injection.

Bioactive hydrogels are a broad and still-evolving category. These synthetic or semi-synthetic polymer gels are designed to provide scaffolding and, in some formulations, to release growth factors or other bioactive signals. Most applications of bioactive hydrogels in cartilage repair remain at the investigational or early clinical-trial stage, particularly outside the knee. They are not yet a standard of care.

Regulatory Status and Approved Applications

ChondroFiller holds Class III CE marking under EU medical device regulations — the highest risk class, requiring the most rigorous pre-market scrutiny. It is indicated for ICRS Grade I to IV articular cartilage defects up to 6 cm² across a range of joints including the knee, hip, ankle, and smaller joints such as the base of the thumb. The Class III CE classification and all published clinical outcome data belong to the ChondroFiller device itself.

Spherox carries regulatory approval for specific knee indications in some European countries. Its approval pathway reflects its cell-therapy classification, which requires different regulatory evidence from a device such as ChondroFiller.

Bioactive hydrogels vary widely by formulation and jurisdiction. Many have not yet completed the regulatory pathways required for routine clinical use, and their availability outside research settings is limited.

What the Evidence Suggests

Published clinical data for ChondroFiller show consistent improvements in validated outcome scores. In knee studies, International Knee Documentation Committee (IKDC) scores have improved by approximately 30 points over 12 to 36 months of follow-up. In hip studies, modified Harris Hip Score (mHHS) improvements of more than 30 points have been reported. MRI-based assessment of cartilage repair tissue quality (MOCART scores) has reached around 80 and above in knee and hip series, indicating good defect fill and integration. A 2023 study on thumb-base osteoarthritis reported significant improvements in pain and grip strength following ChondroFiller injection at that joint (Corain M, Zanotti F, Giardini M, Gasperotti L, Invernizzi E, Biasi V, Lavagnolo U. The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage. 2023). The device's safety record across more than 19,000 units sold since 2013 is notable, with no serious incidents reported and a complaint rate of under 0.1 per cent.

Spherox has demonstrated good outcomes in selected patients with isolated knee cartilage defects, but the two-stage process, the need for cell harvest, and the extended timeline between procedures are factors many patients weigh carefully.

Bioactive hydrogels show promising results in laboratory and early clinical settings, but the evidence base for routine clinical use remains limited. Longer follow-up and larger trials are needed before they can be placed alongside ChondroFiller or Spherox in a clinical comparison.

It is important to note that none of these treatments reverses established osteoarthritis or guarantees cartilage regrowth. Responses vary between individuals, and benefit depends on defect size, location, and patient factors.

Access and Practical Considerations

ChondroFiller is given as a single-stage, ultrasound-guided outpatient injection. No cell harvest, no laboratory preparation, and no second procedure are required. The straightforward delivery pathway tends to mean quicker access, a simpler patient journey, and less overall disruption compared to multi-stage alternatives. It is available for a range of joints, not just the knee.

Spherox involves two clinical appointments separated by several weeks of laboratory processing. This makes it less suitable where a patient needs prompt treatment or cannot commit to a multi-stage pathway. Its current approvals are also largely limited to the knee.

Bioactive hydrogels are predominantly available only within clinical trials or specialist research centres. Patients interested in these approaches should ask whether they meet trial eligibility criteria.

Distinguishing ChondroFiller from Surgical Cartilage Repair

It is worth clarifying where ChondroFiller, as a non-surgical injection, fits in the broader landscape. For accessible defects and smaller joints, the ultrasound-guided ChondroFiller injection is the appropriate pathway — no theatre, no anaesthetic. For larger or load-bearing defects where keyhole surgery is indicated, a different approach called the Liquid Cartilage procedure may be more appropriate. Liquid Cartilage is a keyhole surgical protocol developed at the London Cartilage Clinic that delivers the ChondroFiller scaffold arthroscopically, combined with biological adjuncts and, where indicated, the patient's own mesenchymal stem cells. Liquid Cartilage is a surgical procedure and is distinct from the non-surgical ChondroFiller injection discussed throughout this article. A specialist assessment will determine which pathway suits the particular defect.

Conclusion

Of the non-surgical injectable options currently available, ChondroFiller stands out for its Class III CE-marked regulatory status, its single-stage outpatient delivery, its multi-joint applicability, and its published clinical evidence base. Spherox is an established option for selected knee defects where a cell-based, two-stage approach is appropriate. Bioactive hydrogels remain predominantly investigational. None is a universal solution, and none reverses arthritis.

If you are weighing injectable options for joint cartilage wear, a specialist consultation at the London Cartilage Clinic can help clarify which approach — or which combination — is realistic for your joint and circumstances.

References

Corain M, Zanotti F, Giardini M, Gasperotti L, Invernizzi E, Biasi V, Lavagnolo U. The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage. 2023.